Bhatt, Deepak L.

The optimal management of patients on oral anticoagulation undergoing coronary artery stenting: The 10th Anniversary Overview

Faxon, D., Airaksinen, J., Schlitt, A., Marìn, F., Bhatt, D., Lip, G., & Rubboli, A. (2014) · Thrombosis and Haemostasis

Antiplatelet Therapy and Cardiovascular DiseasesCoronary Interventions and Diagnostics

Cited by 60

Cardiovascular event rates in patients with cerebrovascular disease and atherothrombosis at other vascular locations: Results from 1-year outcomes in the Japanese REACH Registry

Uchiyama, S., Goto, S., Matsumoto, M., Nagai, R., Origasa, H., Yamazaki, T., Shigematsu, H., Shimada, K., Yamada, N., Bhatt, D. L., et al. (2009) · Journal of the Neurological Sciences

Acute Ischemic Stroke ManagementCerebrovascular and Carotid Artery Diseases

Cited by 59

One-year costs associated with cardiovascular disease in Canada: Insights from the REduction of Atherothrombosis for Continued Health (REACH) registry

Smolderen, K. G., Bell, A., Lei, Y., Cohen, E. A., Gabriel Steg, P., Bhatt, D. L., & Mahoney, E. M. (2010) · Canadian Journal of Cardiology

Peripheral Artery Disease ManagementHealth Systems, Economic Evaluations, Quality of Life

Cited by 57

Reduction in Revascularization With Icosapent Ethyl: Insights From REDUCE-IT Revascularization Analyses

Peterson, B. E., Bhatt, D. L., Steg, P. G., Miller, M., Brinton, E. A., Jacobson, T. A., Ketchum, S. B., Juliano, R. A., Jiao, L., Doyle, R. T., et al. (2021) · Circulation

Fatty Acid Research and HealthLipoproteins and Cardiovascular Health

Cited by 57

Prescription of glucagon-like peptide-1 receptor agonists by cardiologists.

Vaduganathan, M., Patel, R. B., Singh, A., McCarthy, C. P., Qamar, A., Januzzi, J. L., Scirica, B. M., Butler, J., Cannon, C. P., & Bhatt, D. L. (2019) · Journal of the American College of Cardiology

Diabetes Treatment and ManagementHeart Failure Treatment and Management

Cited by 55

Effect of Dapagliflozin on Cardiovascular Outcomes According to Baseline Kidney Function and Albuminuria Status in Patients With Type 2 Diabetes: A Prespecified Secondary Analysis of a Randomized Clinical Trial

Zelniker, T. A., Raz, I., Mosenzon, O., Dwyer, J. P., Heerspink, H. H. J. L., Cahn, A., Goodrich, E. L., Im, K., Bhatt, D. L., Leiter, L. A., et al. (2021) · JAMA Cardiology

Diabetes Treatment and ManagementChronic Kidney Disease and Diabetes

Cited by 52

Patient-reported Outcomes After Metabolic Surgery Versus Medical Therapy for Diabetes: Insights From the STAMPEDE Randomized Trial

Aminian, A., Kashyap, S. R., Wolski, K. E., Brethauer, S. A., Kirwan, J. P., Nissen, S. E., Bhatt, D. L., & Schauer, P. R. (2021) · Annals of Surgery

Bariatric Surgery and OutcomesDiabetes Treatment and Management

Cited by 50

Ethnic differences in the prevalence and treatment of cardiovascular risk factors in US outpatients with peripheral arterial disease: Insights from the Reduction of Atherothrombosis for Continued Health (REACH) Registry

Meadows, T. A., Bhatt, D. L., Hirsch, A. T., Creager, M. A., Califf, R. M., Ohman, E. M., Cannon, C. P., Eagle, K. A., Alberts, M. J., Goto, S., et al. (2009) · American Heart Journal

Peripheral Artery Disease ManagementLipoproteins and Cardiovascular Health

Cited by 50

The effect of glucagon‐like peptide‐1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across baseline blood pressure categories: Analysis of the LEADER and SUSTAIN 6 trials

Leiter, L. A., Bain, S. C., Bhatt, D. L., Buse, J. B., Mazer, C. D., Pratley, R. E., Rasmussen, S., Ripa, M. S., Vrazic, H., & Verma, S. (2020) · Diabetes, Obesity and Metabolism

Diabetes Treatment and ManagementBlood Pressure and Hypertension Studies

Cited by 45

Long‐Term Efficacy, Safety, and Tolerability of Alirocumab in 8242 Patients Eligible for 3 to 5 Years of Placebo‐Controlled Observation in the ODYSSEY OUTCOMES Trial

Goodman, S. G., Steg, P. G., Poulouin, Y., Bhatt, D. L., Bittner, V. A., Diaz, R., Garon, G., Harrington, R. A., Jukema, J. W., Manvelian, G., et al. (2023) · Journal of the American Heart Association

Lipoproteins and Cardiovascular HealthAcute Myocardial Infarction Research

Cited by 44

Out-of-Pocket Costs for SGLT-2 (Sodium-Glucose Transport Protein-2) Inhibitors in the United States

Aggarwal, R., Vaduganathan, M., Chiu, N., & Bhatt, D. L. (2022) · Circulation: Heart Failure

Diabetes Treatment and ManagementPharmaceutical Economics and Policy

Cited by 43

Comparison of mineral oil and non-mineral oil placebo on coronary plaque progression by coronary computed tomography angiography

Lakshmanan, S., Shekar, C., Kinninger, A., Dahal, S., Onuegbu, A., Cai, A. N., Hamal, S., Birudaraju, D., Roy, S. K., Nelson, J. R., et al. (2020) · Cardiovascular Research

Cardiac Imaging and DiagnosticsFatty Acid Research and Health

Cited by 42

Alirocumab after acute coronary syndrome in patients with a history of heart failure

White, H. D., Schwartz, G. G., Szarek, M., Bhatt, D. L., Bittner, V. A., Chiang, C.-E., Diaz, R., Goodman, S. G., Jukema, J. W., Loy, M., et al. (2022) · European Heart Journal

Lipoproteins and Cardiovascular HealthAcute Myocardial Infarction Research

Cited by 41

Generalizability of the REDUCE-IT Trial in Patients With Stable Coronary Artery Disease

Picard, F., Bhatt, D. L., Ducrocq, G., Elbez, Y., Ferrari, R., Ford, I., Tardif, J.-C., Tendera, M., Fox, K. M., & Steg, P. G. (2019) · Journal of the American College of Cardiology

Fatty Acid Research and HealthLipoproteins and Cardiovascular Health

Cited by 39

CABG the clear choice for patients with diabetes and multivessel disease

Bhatt, D. L. (2018) · The Lancet

Coronary Interventions and DiagnosticsCardiac and Coronary Surgery Techniques

Cited by 38

REDUCE-IT

Bhatt, D. L. (2019) · European Heart Journal

Fatty Acid Research and HealthLipoproteins and Cardiovascular Health

Cited by 37

Re‐examining the widespread policy of stopping sodium‐glucose cotransporter‐2 inhibitors during acute illness: A perspective based on the updated evidence

Khunti, K., Aroda, V. R., Bhatt, D. L., Bozkurt, B., Buse, J. B., Heerspink, H. L., Inzucchi, S. E., Lam, C. S. P., Marx, N., McMurray, J. J. V., et al. (2022) · Diabetes, Obesity and Metabolism

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 37

Role of High-Dose Beta-Blockers in Patients with Heart Failure with Preserved Ejection Fraction and Elevated Heart Rate

Lam, P. H., Gupta, N., Dooley, D. J., Singh, S., Deedwania, P., Zile, M. R., Bhatt, D. L., Morgan, C. J., Pitt, B., Fonarow, G. C., et al. (2018) · The American Journal of Medicine

Heart Failure Treatment and ManagementHeart rate and cardiovascular health

Cited by 36

Liraglutide Reduces Cardiovascular Events and Mortality in Type 2 Diabetes Mellitus Independently of Baseline Low-Density Lipoprotein Cholesterol Levels and Statin Use: Results From the LEADER Trial

Verma, S., Leiter, L. A., Mazer, C. D., Bain, S. C., Buse, J., Marso, S., Nauck, M., Zinman, B., Bosch-Traberg, H., Rasmussen, S., et al. (2018) · Circulation

Diabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 35

Benefit of icosapent ethyl on coronary physiology assessed by computed tomography angiography fractional flow reserve: EVAPORATE-FFRCT

Rabbat, M. G., Lakshmanan, S., Benjamin, M. M., Doros, G., Kinninger, A., Budoff, M. J., & Bhatt, D. L. (2023) · European Heart Journal - Cardiovascular Imaging

Cardiac Imaging and DiagnosticsCoronary Interventions and Diagnostics

Cited by 34

The cost-effectiveness of dapagliflozin in treating high-risk patients with type 2 diabetes mellitus: an economic evaluation using data from the DECLARE-TIMI 58 trial

McEwan, P., Morgan, A. R., Boyce, R., Bergenheim, K., Gause‐Nilsson, I. A. M., Bhatt, D. L., Leiter, L. A., Johansson, P. A., Mosenzon, O., Cahn, A., et al. (2021) · Diabetes, Obesity and Metabolism

Health Systems, Economic Evaluations, Quality of LifeDiabetes Treatment and Management

Cited by 34

Cardiovascular risk reduction with icosapent ethyl

Patel, P. N., Patel, S. M., & Bhatt, D. L. (2019) · Current Opinion in Cardiology

Fatty Acid Research and HealthLipoproteins and Cardiovascular Health

Cited by 33

Impact of Icosapent Ethyl on Cardiovascular Risk Reduction in Patients With Heart Failure in REDUCE‐IT

Selvaraj, S., Bhatt, D. L., Steg, P. G., Miller, M., Brinton, E. A., Jacobson, T. A., Juliano, R. A., Jiao, L., Tardif, J., Ballantyne, C. M., et al. (2022) · Journal of the American Heart Association

Fatty Acid Research and HealthLipoproteins and Cardiovascular Health

Cited by 31

An Observational Study of Cardiovascular Outcomes of Tirzepatide vs Glucagon-Like Peptide-1 Receptor Agonists

Dani, S. S., Makwana, B., Khadke, S., Kumar, A., Jhund, P., Nasir, K., Sattar, N., Al-Kindi, S., Fonarow, G., Butler, J., et al. (2025) · JACC: Advances

Diabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 30